Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Hold” by Analysts
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review
Nkarta to Participate in March Investor Conferences
Nkarta, Inc. $NKTX Shares Sold by AWM Investment Company Inc.
Nkarta to Participate in Evercore Healthcare Conference
Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
Nkarta to Participate in November Investor Conferences
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
Nkarta to Participate in a September Investor Conference
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Nkarta (NKTX) Upgraded to Buy: Here's Why
Nkarta to Participate in an April Investor Conference
Nkarta: Grinding Lower, Trying To Find Support
Nkarta: Betting On The Turnaround
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nkarta to Participate in March Investor Conferences
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta to Participate in an Upcoming Investor Conference
Nkarta to Participate in an Upcoming Investor Conference
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Nkarta to Participate in Upcoming Investor Conference
Why Nkarta Stock Is Soaring Today
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know
3 Undervalued Stocks Primed for a 2X Return
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
Nkarta: Finally An Attractive Valuation
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors